Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Molhoek, Kerrington R ^a   Brautigan, David L ^b   Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

B Raf; BAY43 9006; Melanoma; MTOR; Rapamycin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADENOSINE TRIPHOSPHATE; B RAF KINASE; GLUTAMIC ACID; INITIATION FACTOR 4E BINDING PROTEIN 1; LUCIFERASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P70; R 5000; RAPAMYCIN; S6 KINASE; SORAFENIB; VALINE;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA CELL; MUTATIONAL ANALYSIS; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; WILD TYPE;

EID: 27744565979     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-39     Document Type: Article

References (41)

1. Rodenhuis, S. (1992). ras and human tumors. Semin Cancer Biol 3, 241-247.
2. Shah, N.P., and Sawyers, C.L. (2003). Mechanisms of resistance to ST1571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389-7395.
3. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., and Futreal, P.A. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
4. Pollock, P.M., and Meltzer, P.S. (2002). A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2, 5-7.
5. Tuveson, D.A., Weber, B.L., and Herlyn, M. (2003). BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95-98.
6. Ahmad T., and Eisen, T. (2004). Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10, 6388S-6392S.
7. Roux, P.P., and Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68, 320-344.
8. Hartkamp, J., Troppmair, J., and Rapp, U.R. (1999). The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res 59, 2195-2202.
9. Burack, W.R., and Sturgill, T.W. (1997). The activating dual phosphorylation of MAPK by MEK is nonprocessive. Biochemistry 36, 5929-5933.
10. Hotte, S.J., and Hirte, H.W. (2002). BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 8, 2249-2253.
11. Krasilnikov, M., Ivanov, V.N., Dong, J., and Ronai, Z. (2003). ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22, 4092-4101.
12. Sansal, I., and Sellers, W.R. (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22, 2954-2963.
13. Xu, G., Zhang, W., Bertram, P., Zheng, X.F., and McLeod, H. (2004). Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24, 893-900.
14. Morris, R.E., Wu, J., and Shorthouse, R. (1990). A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc 22, 1638-1641.
15. Chiaramonte, S., Dissegna, D., and Ronco, C. (2005). Monitoring of immunosuppressive therapy in renal transplanted patients. Contrib Nephrol 146, 73-86.
16. Regar, E., Sianos, G., and Serruys, P.W. (2001). Stent development and local drug delivery. Br Med Bull 59, 227-248.
17. Chan, S. (2004). Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91, 1420-1424.
18. Atkins, M.B., Hidalgo, M., Stadler, W.M., Logan, T.F., Dutcher, J.P., Hudes, G.R., Park, Y., Liou, S.H., Marshall, B., Boni, J.P., Dukart, G., and Sherman, M.L. (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22, 909-918.
19. Peralba, J.M., DeGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G., and Hidalgo, M. (2003). Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res 9, 2887-2892.
20. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., and Armand, J.P. (2004). Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22, 2336-2347.
21. Brinckerhoff, L.H., Kalashnikov, V.V., Thompson, L.W., Yamshchikov, G.V., Pierce, R.A., Galavotti, H.S., Engelhard, V.H., and Slingluff, C.L., Jr. (1999). Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer 83, 326-334.
22. Kittlesen, D.J., Thompson, L.W., Gulden, P.H., Skipper, J.C., Colella, T.A., Shabanowitz, J., Hunt, D.F., Engelhard, V.H., and Slingluff, C.L., Jr. (1998). Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol 160, 2099-2106.
23. Huntington, J.T., Shields, J.M., Der, C.J., Wyatt, C.A., Benbow, U., Slingluff, C.L., Jr., and Brinckerhoff, C.E. (2004). Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 279, 33168-33176.
24. Tallarida, R.J. (2001). Drug synergism: its detection and applications. J Pharmacol Exp Ther 298, 865-872.
25. Lehman, J.A., Calvo, V., and Gomez-Cambronero, J. (2003). Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase. J Biol Chem 278, 28130-28138.
26. Hilger, R.A., Kredtke, S., Scheulen, M.E., Seeber, S., and Strumberg, D. (2004). Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther 42, 648-649.
27. Strumberg, D., Richly, H., Hilger, R.A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C.G., Schwartz, B., Awada, A., Voigtmann, R., Scheulen, M.E., and Seeber, S. (2004). Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. J Clin Oncol.
28. Erhardt, P., Schremser, E.J., and Cooper, G.M. (1999). B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19, 5308-5315.
29. Dancey, J., and Sausville, E.A. (2003). Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2, 296-313.
30. Smalley, K.S. (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104, 527-532.
31. Bjornsti, M.A., and Houghton, P.J. (2004). The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4, 335-348.
32. Margolin, K.A., Longmate, J., Baratta, T., Synold, T., Weber, J., Gajewski, T., Quirt, I., Christensen, S., and Doroshow, J.H. (2004). CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 22, No 14S (July 15 Supplement), Abstract No. 7523.
33. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., and Marais, R. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
34. Flaherty KT, B.M., Schuchter L, Tuveson D, Lee, RJ, Schwartz B, Lathia CD, Weber B, O'Dwyer PJ. (2004). Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22, 7507.
35. Campbell, M., Allen, W.E., Sawyer, C., Vanhaesebroeck, B., and Trimble, E.R. (2004). Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res 95, 380-388.
36. Iijima, Y., Laser, M., Shiraishi, H., Willey, C.D., Sundaravadivel, B., Xu, L., McDermott, P.J., and Kuppuswamy, D. (2002). c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 277, 23065-23075.
37. Pardo, O.E., Arcaro, A., Salerno, G., Tetley, T.D., Valovka, T., Gout, I., and Seckl, M.J. (2001). Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene 20, 7658-7667.
38. Bhandari, B.K., Feliers, D., Duraisamy, S., Stewart, J.L., Gingras, A.C., Abboud, H.E., Choudhury, G.G., Sonenberg, N., and Kasinath, B.S. (2001). Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int 59, 866-875.
39. Naegele, S., and Morley, S.J. (2004). Molecular cross-talk between MEK1/ 2 and mTOR signaling during recovery of 293 cells from hypertonic stress. J Biol Chem 279, 46023-46034.
40. Lehman, J.A., and Gomez-Cambronero, J. (2002). Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem Biophys Res Commun 293, 463-469.
41. Leyland-Jones, B. (2002). Trastuzumab: hopes and realities. Lancet Oncol 3, 137-144.